Eli Lilly and Company

This Phase 2 trial tests an experimental drug called LY3457263 in 240 adults with type 2 diabetes who still have high blood sugar despite taking stable doses of semaglutide or tirzepatide. Participants receive weekly injections of either the new drug or a placebo for about 9 mont…

This study tests whether the drug tirzepatide, given once weekly, helps adults with obesity (but without diabetes) lose weight and avoid developing type 2 diabetes. About 3,000 participants will receive either tirzepatide or standard care for up to 5 years. The goal is to see if …

This study tests whether baricitinib, a daily pill, can safely regrow hair in children aged 6 to 17 with severe alopecia areata (patchy hair loss). About 595 kids will receive either the drug or a placebo for 36 weeks, then all can get the drug for up to 2 years. The goal is to s…

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This study tests an oral drug called LY4268989 (MORF-057) in adults with moderate-to-severe ulcerative colitis. About 1,431 participants will receive either the drug or a placebo for up to 108 weeks. The goal is to see if the drug can safely help control the disease and improve s…

This study tests an experimental drug called LY4005130 in 60 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants receive either the drug or a placebo by IV every few weeks for 24 weeks. The goal is to see if the drug can reduce the …

This study looks at whether adding tirzepatide (a weight-loss drug) to standard ixekizumab treatment helps adults with active psoriatic arthritis who are overweight or obese. About 200 participants will receive both medications for up to 12 months. The goal is to see if this comb…

This study tests whether adding a new drug (LY4395089) to an existing treatment (mirikizumab) works better than mirikizumab alone for adults with moderate-to-severe Crohn's disease. About 60 participants will be followed for 62 weeks to check safety and how well the combination r…

This large phase 3 study is testing whether two drugs, tirzepatide and retatrutide, can prevent major liver complications in 4,500 adults with high-risk metabolic fatty liver disease (MASLD). Participants are randomly assigned to receive one of the drugs or a placebo for about 4 …

This study tests a new drug called LY4005130 for adults with severe alopecia areata, a condition causing significant hair loss. About 60 participants will receive either the drug or a placebo intravenously. The goal is to see if the drug can regrow hair and to check for side effe…

This Phase 2 trial is testing several experimental drugs—including tirzepatide and others—for long-term weight management in adults with obesity or overweight. About 1,481 participants will receive one of the drugs or a placebo. The goal is to see if these treatments are safe and…

This phase 3 trial tests a weekly injection called eloralintide in 800 adults with moderate-to-severe obstructive sleep apnea who are also overweight or have obesity. The study looks at whether the drug can improve sleep apnea symptoms and help with weight loss. Participants are …

This study tests a new weekly injection called eloralintide in 900 adults with obesity or overweight who are already taking a weekly incretin drug (like Ozempic or Wegovy) but still have excess weight. Participants will receive either eloralintide or a placebo for about 80 weeks …

This Phase 3 study tests whether adding olomorasib (a targeted pill) to standard immunotherapy (pembrolizumab or durvalumab) works better than immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer. The trial has two parts: one for patients whose cancer w…

This global study is testing whether adding the experimental drug olomorasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C mutation). About 1,264 participants will receive either the ne…

This study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 340 adults whose cancer has not responded to standar…

This study tests two experimental drugs, macupatide and eloralintide, alone or together, to help adults with obesity or overweight and type 2 diabetes lose weight. About 200 participants will receive the drugs or a placebo for 48 weeks. The main goal is to see how much weight the…

This study tests a new once-weekly medicine called eloralintide to help people with obesity or overweight and type 2 diabetes lose weight. About 1035 adults will receive either the drug or a placebo for around 75 weeks. Researchers will measure changes in body weight, fat, waist …

This study tests a once-daily pill called orforglipron in adults with type 2 diabetes who plan to fast during Ramadan. The goal is to see if the drug helps control blood sugar and weight without causing harm. About 130 participants will take the pill for up to 48 weeks, with clin…

This study tests an injectable drug called solbinsiran in 60 adults with severe hypertriglyceridemia (very high blood fats). Participants receive two shots of either the drug or a placebo. The goal is to see if solbinsiran safely lowers triglycerides and related fats better than …

This study is testing a new experimental drug called LY4584180 in adults with certain types of blood cancer (like lymphoma) that have not improved after at least two prior treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shr…

This study tests a daily pill called orforglipron to see if it can prevent major heart problems (like heart attacks or strokes) and slow kidney disease in people who already have heart or kidney disease. About 7,140 adults will take either the drug or a placebo for up to 5 years.…

This early-stage trial tests a new drug called LY4152199 in about 215 adults with certain types of blood cancer (like follicular lymphoma or diffuse large B-cell lymphoma) that have already been treated. The drug is designed to help the body's immune cells attack the cancer. The …

This phase 2 trial tests whether donanemab, an antibody given by IV, can slow worsening of thinking and daily function in people with early cognitive decline and Lewy body dementia. The study enrolls 350 participants who also have signs of two brain proteins (amyloid and alpha-sy…

This study tests a drug called lepodisiran in 252 adults with high levels of Lp(a), a protein linked to heart disease. Participants must have heart disease or be at risk for a first heart event. The drug is given as an injection and compared to a placebo to see if it reduces plaq…

This phase 2 study is testing two new drugs — mirikizumab (given by IV or injection) and LY4395089 (a pill) — in 60 adults with moderately to severely active ulcerative colitis or Crohn's disease. The goal is to see if these treatments are safe and can help control the disease. T…

This large Phase 3 study tests a new medicine called Sofetabart Mipitecan for people with ovarian, fallopian tube, or peritoneal cancer. It includes two groups: those whose cancer stopped responding to platinum chemotherapy within six months (platinum-resistant), and those whose …

This study tests whether adding a new drug (LY4064809) to standard hormone therapy and CDK4/6 inhibitors can better control advanced HR+ HER2- breast cancer with a PIK3CA mutation. About 920 adults who have not had prior treatment for advanced disease will participate. The goal i…

This study tests whether adding a new oral drug, LY4268989, to the existing treatment mirikizumab works better than mirikizumab alone for adults with moderate-to-severe ulcerative colitis. About 252 participants will receive either the combination or mirikizumab plus a placebo fo…

This study tests an investigational drug called lebrikizumab in people with long-term sinus inflammation and nasal polyps. About 510 adults will receive either the drug or a placebo, while all continue using standard steroid nasal sprays. The goal is to see if the drug can improv…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This study tests whether adding the drug brenipatide to standard treatment can delay the return of bipolar symptoms compared to a placebo. About 400 adults with bipolar I or II will self-inject the study drug or placebo for at least 6 months. The main goal is to see how long it t…

This study is testing whether adding the weight-loss drug tirzepatide to the standard psoriasis medication ixekizumab helps people with moderate-to-severe plaque psoriasis who are also overweight or obese. About 200 adults will receive tirzepatide injections for up to 12 months. …

This phase 3 trial tests whether adding tirzepatide (a weight-loss drug) to mirikizumab (an anti-inflammatory drug) helps people with moderate-to-severe ulcerative colitis who are also overweight or obese. The goal is to see if the combination can reduce both gut symptoms and bod…

This study is checking the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with other drugs. About 150 adults who completed a previous pirtobrutinib study can join. They…

This Phase 3 trial tests an oral drug called muvalaplin in over 10,000 adults with high levels of lipoprotein(a), a genetic risk factor for heart disease and stroke. Participants either have had a prior cardiovascular event or are at high risk for a first one. The study measures …

This study tests whether baricitinib, a pill, can help preserve the body's ability to make insulin in people newly diagnosed with type 1 diabetes. About 300 children and young adults (ages 1 to under 36) will take either baricitinib or a placebo for 60 weeks. The goal is to see i…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This study tests a new oral drug called imlunestrant in premenopausal women with estrogen receptor-positive, HER2-negative breast cancer. Some participants will also receive a drug to suppress ovarian function. The effects on tumor cells and ovaries will be compared with those of…

This study tests whether adding the weight-loss drug tirzepatide to the Crohn's drug mirikizumab helps people with moderate-to-severe Crohn's disease who are also overweight or have obesity. About 290 adults will receive either mirikizumab alone or mirikizumab plus tirzepatide. T…

This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…

This study tests whether adding brenipatide to standard schizophrenia medication is safe and effective. About 450 adults with schizophrenia will receive either brenipatide or a placebo for up to 12 months. The study looks at weight changes, cognitive function, and time to relapse…

This Phase 2 trial tests whether adding brenipatide to standard buprenorphine treatment helps people with opioid use disorder stay off opioids longer. About 465 participants will receive either brenipatide or a placebo injection alongside their usual medication. The study measure…

This phase 3 study tests whether brenipatide can help adults with moderate-to-severe alcohol use disorder drink less and feel less urge to drink. About 1,100 motivated participants will receive either the drug or a placebo for 56 weeks. The main goal is to see changes in drinking…

This study tests whether a weekly injection of tirzepatide, combined with healthy eating and exercise, helps adolescents with obesity and related conditions like high blood pressure or prediabetes lose weight and improve their health. About 300 teens who completed a prior study c…

This early-stage study tests an experimental drug called LY4298445 in healthy volunteers and people with lupus or rheumatoid arthritis. The main goal is to check safety and how the body handles the drug. Participants will receive either the drug or a placebo, and the study lasts …

This early-stage study tests an experimental drug called LY4174794 in 108 healthy volunteers who are overweight or have obesity. The main goal is to check the drug's safety and how the body processes it, not to measure weight loss. Participants will receive either the drug or a p…

This Phase 3 trial is testing an oral medication called orforglipron for chronic weight management in children and teens with obesity or overweight. The study will enroll 125 participants who have already tried lifestyle changes without success. The goal is to see if the drug is …

This early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. The main goals are to check safety and see if the drug shrinks tumors, given alone or with chemoth…

This study looks at the long-term safety and effectiveness of the drug baricitinib for children aged 1 to 17 with juvenile idiopathic arthritis (JIA). It includes 190 participants who have already taken baricitinib in a previous study. Researchers will monitor side effects and ho…

This study looks at the long-term safety of an experimental drug called LY4256984 for people with ALS. It enrolls up to 32 participants who have completed a prior ALS trial. The study will follow them for at least 96 weeks to see how well the drug is tolerated over time.

This early-stage study tests a new drug called LY3954068 in 48 people with mild Alzheimer's symptoms. The drug is given directly into the spinal fluid, either once or twice, to see if it is safe and how it affects Alzheimer's markers. The study lasts up to 100 weeks and includes …

This study tests donanemab, an experimental drug, against a placebo in 140 Chinese adults who show early signs of Alzheimer's risk. Participants receive the drug intravenously every few weeks for up to 3 years. The goal is to see if donanemab can delay memory loss and help mainta…

This study tests the long-term safety of a drug called LY4256984, given via spinal injection, in people with ALS. It includes 32 participants who completed an earlier study and will be followed for about 96 weeks. The main goal is to see how many people have serious side effects …

This phase 3 trial tests mirikizumab, an injected drug, in 90 children with moderate-to-severe Crohn's disease. The study looks at whether the drug can improve symptoms and heal the gut lining over 52 weeks. Participants receive mirikizumab during a 12-week induction period, then…

This study tests a once-daily pill called orforglipron to help teenagers with obesity or overweight lose weight. About 150 teens will take either the pill or a placebo for 18 months, along with lifestyle advice. The goal is to see if the pill safely reduces body mass index (BMI) …

This study tests the long-term safety and effectiveness of mirikizumab in 150 children and adolescents with moderate-to-severe ulcerative colitis or Crohn's disease. Participants who completed earlier mirikizumab studies can join. The trial lasts about 172 weeks and aims to see i…

This early-stage trial will test a single dose of a new drug called LY3971297 in 90 people with two types of heart failure: preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF). The main goal is to see if the drug is safe and what side effects occur. Particip…

This study tests an experimental medicine called brenipatide to see if it helps adults with alcohol use disorder drink less and reduce cravings. About 1,100 participants will receive either the drug or a placebo by injection for nearly a year. The goal is to find a safe, effectiv…

This study tests whether adding a new targeted medicine (vepugratinib) to two standard cancer drugs can help people with advanced bladder cancer that has a specific genetic change (FGFR3). About 450 adults whose cancer has spread or cannot be removed by surgery will take part. Th…

This study tests whether the experimental drug brenipatide can reduce asthma attacks and improve breathing in adults whose moderate-to-severe asthma is not well controlled by current treatments. About 531 participants will receive either brenipatide or a placebo for 52 weeks. The…

This study tests a new once-weekly injection called eloralintide to help adults with obesity or overweight lose weight. About 1980 people who do not have type 2 diabetes will take part for up to 75 weeks, with some continuing for 2 more years. The goal is to see if the drug safel…

This early-stage trial is testing a new oral drug called LOXO-435, alone or with other cancer medicines, in people with advanced solid tumors that have a specific change in the FGFR3 gene. The study aims to find the right dose and check for safety and early signs of effectiveness…

This early-stage trial is testing whether an investigational drug called eloralintide can slow down how quickly the stomach empties, which may help people feel fuller longer and support weight management. The study involves about 56 adults who are overweight or have obesity but a…

This study tests two higher doses (3.0 mg and 4.5 mg) of the diabetes drug dulaglutide in teenagers aged 10 to 17 with type 2 diabetes. The goal is to see if these doses are safe and help control blood sugar and weight. Participants will receive weekly injections for about 8 mont…

This trial tests several cancer drugs in children and young adults with solid tumors. It uses a master protocol to test different drug combinations more efficiently. About 105 participants will receive one of eight drugs, including ramucirumab, cyclophosphamide, and others. The g…

This study tests whether adding a new drug called brenipatide to standard depression treatment can delay the return of major depressive symptoms. About 1000 adults with major depression who are already on stable medication will receive either brenipatide or a placebo as a shot, p…

This program allows individual patients with serious or life-threatening conditions to request early access to retatrutide before it is fully approved. The drug is intended to help control the disease, but ongoing management may still be needed. Eligibility is determined on a cas…

This Phase 2b trial is testing whether two experimental drugs, macupatide and eloralintide, can help adults with obesity or overweight lose weight. About 400 participants will receive either one or both drugs or a placebo for 64 weeks. The study measures weight change and safety,…

This study tests two drugs, eltrekibart and mirikizumab, alone or together, in 140 adults with moderate-to-severe ulcerative colitis. The goal is to see if they can safely reduce inflammation and help patients achieve remission. Participants must have tried other treatments witho…

This early-stage study tests whether a new drug, eloralintide, can improve how the body responds to insulin and manage weight in 115 adults with overweight or obesity. Participants will receive either the drug or a placebo injection and be monitored for about 35 weeks. The goal i…

This study tests a new drug called STX-478 in people with advanced solid tumors that have a specific genetic change (PI3Kα mutation). The trial has two phases: first, it tests STX-478 alone to find safe doses; then, it combines STX-478 with other cancer drugs like fulvestrant or …

This study tests whether people with Alzheimer's who already took the drug donanemab benefit from getting it just once a year. About 550 volunteers who finished a previous donanemab study will receive either the drug or a placebo for up to 2.5 years. Researchers will track change…

This expanded access program provides vepugratinib, an oral drug, to people with metastatic urothelial carcinoma or other solid tumors that have a specific FGFR3 genetic change. Participants must have exhausted other approved treatments, including erdafitinib for bladder cancer, …

This study tests a drug called pirtobrutinib in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The trial has two parts: first, finding safe doses, then comparing pirtobrutinib to a placebo to see if it ra…

This early-stage study tests a new drug called LY4213663 in healthy volunteers and people with rheumatoid arthritis (RA). The main goal is to see if the drug is safe and what side effects it may cause. Researchers will also measure how the body processes the drug. The study lasts…

This study offers continued access to experimental oral cancer drugs for patients who are already benefiting from them in a previous Lilly study. The main goal is to monitor long-term safety. Participants must not be in any other conflicting research.

This early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard…

This early-stage study tests a new drug called LY4006895 in healthy volunteers and people with early symptomatic Alzheimer's disease. The main goal is to check if the drug is safe and how the body processes it. The study has two parts: a single dose in healthy people and multiple…

This early-stage trial is testing an experimental drug called LY4006896 in healthy volunteers and people with Parkinson's disease. The main goal is to check if the drug is safe and how the body processes it. Researchers will give single or multiple doses and watch for side effect…

This early-stage study tests a new drug called LY4256984 in 32 people with sporadic ALS. The drug is injected into the spine to see if it is safe and how the body handles it. The main goal is to check for side effects, not yet to prove it works.

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia or non-Hodgkin lymphoma. About 787 participants who completed an earlier pirtobrutinib study can join to keep receiving treatment or have follow-up visits. The main goal…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were already in a previous trial. About 279 participants will continue their treatment or follow-up visits. The main goal is to t…

This early-stage study tests an experimental drug called LY3938577 in healthy volunteers and people with type 1 diabetes. The main goals are to see how the body processes the drug and whether it can safely lower blood sugar. The study has four parts, comparing the drug to insulin…

This study is testing whether adding the drug donanemab to standard care helps people with early Alzheimer's stay independent longer. Researchers will follow about 6,250 participants for over 5 years, tracking when they need more help with daily tasks. The goal is to see if donan…

This early-stage study tests a new injection called [18F]LY4214835 to see if it is safe and how it spreads in the body. It includes healthy volunteers and people with cancer. The goal is to improve how doctors see tumors using imaging scans.

This study is testing whether a blood test for a protein called P-tau217 can help doctors make faster and better decisions for people with memory concerns. Researchers will compare what happens when doctors have the test results versus standard care. The study involves 7,000 part…

This study tests whether the drug baricitinib can delay the onset of type 1 diabetes in children aged 1 to 36 months who are at high risk. Participants take baricitinib or a placebo daily for up to 5 years. The goal is to see if the drug can push back or prevent the need for insu…

This Phase 2 trial is testing four experimental drugs (taken orally or by IV) against placebo in 10,000 people with chronic pain from knee osteoarthritis, diabetic nerve damage, or low-back pain. The goal is to see if any of these drugs can safely reduce pain. The study uses a fl…

This Phase 2 study tests whether brenipatide, given as an injection under the skin, can safely reduce abdominal pain and improve stool consistency in adults with diarrhea-predominant irritable bowel syndrome (IBS-D). About 531 participants will receive either the drug or a placeb…

This study tests an injected drug called brenipatide in 342 adults with irritable bowel syndrome with constipation (IBS-C). Participants will receive either the drug or a placebo for about 35 weeks. The goal is to see if brenipatide safely reduces abdominal pain and improves bowe…

This study tests whether a once-daily pill called orforglipron can reduce stress urinary incontinence (leaking urine during movement) in women with obesity or overweight. About 1000 adult women will receive either the drug or a placebo for about 58 weeks. The main goal is to see …

This study tests a once-daily pill called orforglipron in about 1205 people with peripheral artery disease (PAD) who have leg pain when walking. The goal is to see if the drug helps them walk farther without pain and improves their quality of life. Participants will be followed f…

This study tests a once-daily pill called orforglipron in 800 adults with obesity or overweight who also have painful knee osteoarthritis. The goal is to see if the drug reduces knee pain and improves physical function over about 74 weeks. Participants will be randomly assigned t…

This Phase 3 study tests a once-weekly injection called eloralintide in 900 adults with osteoarthritis of the knee who are also overweight or obese. The goal is to see if it reduces knee pain and helps with weight loss compared to a placebo. Participants will be in the study for …

This Phase 2 trial tests an experimental oral drug, LY4065967, for knee pain caused by osteoarthritis. About 150 adults with chronic knee pain and confirmed osteoarthritis will receive either the drug or a placebo. The main goal is to see if the drug safely reduces pain intensity…

This Phase 2 trial tests an oral drug called LY4065967 in 150 people with chronic low back pain lasting at least 3 months. Half will get the drug, half a placebo, to see if it safely reduces pain and improves daily function. The study is not yet recruiting.

This study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…

This study tests a drug called brenipatide against a placebo to see if it can help adults who have recently quit smoking stay smoke-free. About 222 participants will receive injections for 24 weeks and be followed for 8 more weeks. The main goal is to see if more people remain ab…

This study tests whether a new drug called LY4065967 can safely reduce nerve pain in people with diabetes. About 150 adults with diabetic nerve pain in their legs for at least 6 months will receive either the study drug or a placebo. The main goal is to see if the drug lowers ave…

This Phase 2 trial tests a single oral dose of LY4515100 against a placebo in 212 people with moderate-to-severe pain after having their wisdom teeth removed. The goal is to see if the drug safely reduces pain intensity and how quickly it works. Participants stay in a research un…

This early-stage study tests a new drug called LY4057996 in 124 healthy volunteers and people with type 1 or type 2 diabetes. The main goal is to see if the drug is safe and what side effects it may cause. Participants receive the drug as a shot under the skin or into a vein, and…

This study will measure how much of the drug mirikizumab passes into breast milk in 14 breastfeeding women who take it for inflammatory bowel disease. Participants will provide milk samples over several weeks. The goal is to understand potential exposure to nursing infants, helpi…

This early-stage study is testing an experimental drug called LY3439539 in 30 people with mild-to-moderate Alzheimer's disease. The main goal is to see if the drug changes certain proteins in the spinal fluid that are linked to Alzheimer's. Participants will receive the drug thro…

This early-stage trial evaluates the safety and tolerability of a new drug called LY4178256 in healthy volunteers. Participants receive either the drug or a placebo intravenously, and researchers monitor side effects and how the body processes the drug. The study lasts about 7 mo…

This early-phase study tests an experimental oral drug called LY4268989 (MORF-057) in 50 healthy adults. Researchers want to see if two different tablet forms are processed similarly by the body, and how meals affect that process. Participants will stay at a research unit for 18 …

This early-stage trial studies how healthy adults process two different liquid versions of the experimental drug eloralintide. The goal is to compare their safety and how the body absorbs and clears each version. Participants receive a single injection and are monitored for about…

This early-stage study tests a new drug called LY4088044 in healthy adults to see if it is safe and how the body handles it. About 104 participants will receive the drug or a placebo, either as a shot under the skin or into a vein. The study lasts up to 92 weeks and focuses on si…

This early-phase trial is testing a new drug called LY4515100 in 40 healthy adults to see if it is safe and how the body handles it. Participants will receive either the drug or a placebo and stay overnight for monitoring. The study does not aim to treat any disease, but to gathe…

This 7-year study follows 3,400 adults who report no memory problems but may be at risk for Alzheimer's. Researchers will use a blood test measuring P-tau217, a protein linked to Alzheimer's, to see if higher levels predict faster cognitive decline. The goal is to better understa…

This early-phase trial is testing the safety and tolerability of a new drug called LY4302814 in 150 healthy volunteers. Participants will receive either the drug or a placebo, and researchers will monitor side effects and how the body processes the drug. The study lasts about 6 m…

This early-stage study is testing a single dose of the drug eloralintide in 36 people with different levels of liver function—from healthy to severely impaired. Researchers want to see how the body absorbs and processes the drug and whether it causes side effects. The goal is to …

This early-stage study in 450 healthy volunteers checks if a single injection of mirikizumab works as well as two separate shots. The main goal is to see how the body handles the drug and to ensure safety. Participants will be monitored for about 15 weeks with blood tests and che…

This early-stage study tests the safety of a new drug called LY4066708 in 104 healthy people. Researchers will measure how much drug enters the blood and brain, and how fast the body clears it. The study lasts up to 24 weeks and does not aim to treat any disease, but will help gu…

This study looks at how a drug called LY3537031 moves through the body in people with mild, moderate, or severe liver problems compared to healthy volunteers. About 32 adults will receive a single injection under the skin. The goal is to understand how liver function affects drug…